Dissertation > Excellent graduate degree dissertation topics show

Tolerability and Early Efficacy of Pegylated Consensus Interferon-α (PEG-CIFN) in the Treatment of Chronic Hepatitis C

Author: ChenHong
Tutor: DingYanHua
School: Jilin University
Course: Internal Medicine
Keywords: recombinant consensus interferon tolerability adverse event early efficacy
CLC: R512.63
Type: Master's thesis
Year: 2013
Downloads: 21
Quote: 0
Read: Download Dissertation

Abstract


Background:Hepatitis C is a challenge worldwide, approvedanti-HCV medications hasn’t been shown to be efficacious to allpatients.Some where are difficult to treat could benefit from Consensusinterferon (CIFN), pegylated CIFN were expected to be more effectiveand safer.Objective:To explore and evaluate the tolerance and antiviralactivity of pegylated recombinant human consensus interferon-α variant（PEG-CIFN）in adults with HCV infection and develop a new safer andmore effective peginterferon.Methods:48adult subjects chronically infected with HCV weretreated by a new peg-interferon(The recombinant human consensusinterferon-α variant (PEG-CIFN)）in a phase one clinical trial. They weredivided into5groups：PEG-CIFN1.0μg/kg (10people), PEG-CIFN1.5μg/kg(10people), PEG-CIFN2.0μg/kg (9people), PEG-CIFN3.0μg/kg (10people) for dose escalation, Pegasys180μg (9people) is positivecontrol.The subjects were treated for4weeks in PEG-CIFN3.0μg/kggroup to evaluate tolerance. The other subjects were treated for14weekswith subcutaneously once a week and were not given drug at the secondand14thweek due to pharmacokenatic blood collection. Symptoms wereobserved and laboratory tests, collected to monitor adverse reactions andadjusting drug dosage, and to evaluate safety and tolerance. HCV RNA level were tested by COBAS Taqman HCV Test system of Roche at the0thweek,4thweek,8thweek and14thweek.Results:Adverse events were well tolerated and none led todiscontinuation of treatment in all dose groups in study period. Theeffects of all PEG-CIFN groups on Platelet drop is weaker than that of Pegasys.The Rapid virologic response (RVR) of PEG-CIFN1.5μg/kg group,PEG-CIFN2.0μg/kg group,PEG-CIFN3.0μg/kg and Pegasys180μg groupwere70%(7/10),77.8%(7/9),(60%,6/10),77.8%(7/9) respectively. They weresignificantly higher than that in PEG-CIFN1.0μg/kg group (10%,1/10)(p<0.05).The Extended rapid virologic response (eRVR) of PEG-CIFN1.0μg/kg group, PEG-CIFN1.5μg/kg group, PEG-CIFN2.0μg/kg groupand Pegasys180μg group were10%(1/10),70%(7/10),77.8%(7/9),66.7%(6/9)respectively.The Early virologic response (EVR) of PEG-CIFN1.0μg/kggroup, PEG-CIFN1.5μg/kg group, PEG-CIFN2.0μg/kg group and Pegasys180μg group were30%(3/10),90%(9/10),88.8%(8/9),88.8%(8/9) respectively.Conclusions:PEG-CIFN (1.0,1.5,2.0,3.0μg/kg)was well toleratedand was found to have dose-dependent effectiveness in chronic hepatitisC subjects.The virological response rates between PEG-CIFN1.5,2.0μg/kg and pegylated IFNα-2a are close, there were no statisticaldifference. The patients who infected1b HCV may have good curativeeffect. Comprehensive consideration, PEG-CIFN1.5μg/kg can be usedas clinical recommended dose. In the treatment of4weeks,8weeks,14weeks, PEG-CIFN is superior to pegylated IFNα-2a in maintainingplatelet levels.

Related Dissertations

  1. Development of On-line Reporting System for Medical Device Adverse Event,TP311.52
  2. Hospital care Adverse Event Reporting System Network Design and Implementation,TP311.52
  3. Research on incentive and Restraint Policy for Medical Adverse Event Reporting of Hospitals,R197.3
  4. The Study of Application JCI Standard in Patient Safety Management,R197.3
  5. Simultaneous Confidence Intervals for Multivariate Binomial Proportions,O211.3
  6. The Designing and Implementation of Workflow-based Integrated TCM Clinical System,TP311.52
  7. 6-week, Randomized, Opened, Comparison of the Efficacy and Tolerability of Ziprasidone and Olanzapine in Schizophrenic,R749.3
  8. Sufficient Conditions for k-Restricted Edge Connectivity to Be λ_k-Optimal and Super-λ_k in Graphs,O157.5
  9. Nurses’ Perception of Patient Safety Culture and the Status of Nursing Adverse Events Reporting,R47
  10. Medical Institutions in Beijing Third Grade Class Medical Device Adverse Event Monitoring Survey Work,F203
  11. Experimental Study on Effects of Oral Rehydration Salt Combined with Carbachol in Resuscitation of Burns Shock,R644
  12. A Investigation of the Status on the Construction of Technical Organization for Medical Device Postmarket Monitoring in XinJiang,F203
  13. The Clinical Value of Autoantibodies against β1-adrenoreceptor in Patients with Chronic Heart Failure,R541.6
  14. Safety Study of Traditional Medicine in Treatment of Rheumatoid Arthritis,R259
  15. The Experimental Study on Gut Tolerance to Early Enteral Nutrition Following Intestinal Ischemia and Reperfusion,R574
  16. The Efficacy of rhIL-11 in the Management of Postremission Consolidation Chemotherapy-Induced Thrombocytopenia in Acute Myeloid Leukemia,R733.71
  17. Phase Ⅰ Trial of Human Tolerability and Pharmacokinetics to Gambogic Acid,R96
  18. Effects of Transnasal Butorphanol on Postoperative Pain,R614
  19. Quality Control and Management of the Abnormal Operation of Micro Syringe Pumps,R472
  20. HCV NS2TP Gene Regulation Mechanism,R512.63
  21. HCV Viral Load and Subtypes among HCV Mono-infected and HIV/HCV Co-infected Patients,R512.63
  22. Effect of Hepatitis C Virus NS5A Protein on TLR3,TLR4,R512.63

CLC: > Medicine, health > Internal Medicine > Infectious disease > Viral infections > Viral Hepatitis > Hepatitis C (non- A non-B )
© 2012 www.DissertationTopic.Net  Mobile